U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4F10
Molecular Weight 238.0268
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERFLUBUTANE

SMILES

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F

InChI

InChIKey=KAVGMUDTWQVPDF-UHFFFAOYSA-N
InChI=1S/C4F10/c5-1(6,3(9,10)11)2(7,8)4(12,13)14

HIDE SMILES / InChI

Molecular Formula C4F10
Molecular Weight 238.0268
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Perfluorobutane (PFB) is an inert, high-density colorless gas used as a replacement for Halon 1301 in fire extinguishers, as well as the gas component for newer generation microbubble ultrasound contrast agents. Perflubutane has been used in clinical trials for the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. Perflubutane perfusion echocardiography has the potential to be a cost-effective and convenient alternative to nuclear perfusion imaging. Ultrasound enhanced with Perflubutane was able to image myocardial perfusion and obtain information that appears comparable to nuclear imaging.

Approval Year

PubMed

PubMed

TitleDatePubMed
Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ.
2014-09-15
Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.
2013-06-07
Diagnostic value of sonazoid for hepatic metastasis: comparison with FDG PET/CT.
2011-03-18
Cooperative infrared to visible up conversion in Tb3+, Eu3+, And Yb3+ containing polymers.
2010-12-14
Contrast-enhanced ultrasonography for characterization of focal splenic lesions in dogs.
2010-11-03
Distribution and sources of polyfluoroalkyl substances (PFAS) in the River Rhine watershed.
2010-10
Ultrasound-induced dissolution of lipid-coated and uncoated gas bubbles.
2010-09-21
Microfluidic assembly of monodisperse, nanoparticle-incorporated perfluorocarbon microbubbles for medical imaging and therapy.
2010-09-07
Spatial distribution and sources of perfluorochemicals in the NW Mediterranean coastal waters (Catalonia, Spain).
2010-09
Ecotoxicological assessment of surfactants in the aquatic environment: combined toxicity of docusate sodium with chlorinated pollutants.
2010-09
Preserving enhancement in freeze-dried contrast agent ST68: Examination of excipients.
2010-08-30
Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent.
2010-08
Perfluorinated compounds in urban river sediments from Guangzhou and Shanghai of China.
2010-06
Polyfluoroalkyl compounds in landfill leachates.
2010-05
Contrast enhanced ultrasound of hepatocellular carcinoma.
2010-02-28
Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model.
2010-01
Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles.
2009-11
Perfluorinated compounds in sediments from the Daliao River system of northeast China.
2009-10
Significance of imaging features of alveolar echinococcosis in studies on nonhuman primates.
2009-09
Polyfluorinated compounds in waste water treatment plant effluents and surface waters along the River Elbe, Germany.
2009-09
One-year follow-up of perfluorinated compounds in plasma of German residents from Arnsberg formerly exposed to PFOA-contaminated drinking water.
2009-09
Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures.
2009-09
Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial.
2009-07
Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT.
2009-04
A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.
2009-02-04
Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging.
2009-01
Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods.
2009-01
Optical microscopic findings of the behavior of perflubutane microbubbles outside and inside Kupffer cells during diagnostic ultrasound examination.
2008-12
Removal of perfluorinated surfactants by sorption onto granular activated carbon, zeolite and sludge.
2008-08
Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000-2006.
2008-07-01
Developmental neurotoxicity of perfluorinated chemicals modeled in vitro.
2008-06
Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging.
2008-05
Acute and chronic effects of perfluorobutane sulfonate (PFBS) on the mallard and northern bobwhite quail.
2008-04
Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography.
2008-03
Pharmacokinetics of perfluorobutane following intravenous bolus injection and continuous infusion of sonazoid in healthy volunteers and in patients with reduced pulmonary diffusing capacity.
2008-03
Combining perfluoroalkane acid exposure levels for risk assessment.
2007-12
[Basic and clinical profile of perflubutane (Sonazoid powder for injection)].
2007-11
Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle.
2007-08-03
Enhanced targeting of ultrasound contrast agents using acoustic radiation force.
2007-07
Release of cardiac bio-markers during high mechanical index contrast-enhanced echocardiography in humans.
2007-05
AI-700 pharmacokinetics, tissue distribution and exhaled elimination kinetics in rats.
2007-01-02
Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow.
2006-12-29
Gateways to clinical trials.
2006-12
Microbubbles which bind and protect DNA against nucleases.
2006-11-28
Microvascular behavior and effects of sonazoid microbubbles in the cremaster muscle of rats after local administration.
2006-07
Molecular mechanics (MM4) study of fluorinated hydrocarbons.
2006-06-08
Atmospheric chemistry of N-methyl perfluorobutane sulfonamidoethanol, C4F9SO2N(CH3)CH2CH2OH: kinetics and mechanism of reaction with OH.
2006-03-15
Value of adenosine infusion for infarct size determination using real-time myocardial contrast echocardiography.
2006-02-08
Disposition of perfluorobutane in rats after intravenous injection of Sonazoid.
2006-01
Tissue distribution of perfluorinated chemicals in harbor seals (Phoca vitulina) from the Dutch Wadden Sea.
2005-09-15
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:26:16 GMT 2025
Edited
by admin
on Mon Mar 31 18:26:16 GMT 2025
Record UNII
SE4TWR0K2C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SONAZOID
Preferred Name English
PERFLUBUTANE
DASH   INN   JAN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
AI-700
Code English
PERFLUBUTANE [JAN]
Common Name English
Decafluorobutane
Systematic Name English
perflubutane [INN]
Common Name English
PERFLUBUTANE [USAN]
Common Name English
Perflubutane [WHO-DD]
Common Name English
BUTANE, DECAFLUORO-
Systematic Name English
PERFLUBUTANE [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC V08DA06
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
NCI_THESAURUS C390
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
Code System Code Type Description
PUBCHEM
9638
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
CAS
355-25-9
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
SMS_ID
100000128614
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID5059876
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
FDA UNII
SE4TWR0K2C
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
CHEBI
134964
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-580-3
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
EVMPD
SUB35893
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
MESH
C069727
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
WIKIPEDIA
PERFLUOROBUTANE
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
NCI_THESAURUS
C76636
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
HSDB
7868
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
USAN
QQ-83
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
INN
8465
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
DRUG BANK
DB12821
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104979
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
MESH
C108042
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
DRUG CENTRAL
3999
Created by admin on Mon Mar 31 18:26:16 GMT 2025 , Edited by admin on Mon Mar 31 18:26:16 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY